Improving D-Allulose Biosynthesis by Growth-Coupled Evolutionary Pressure on Epimerase Using Biosen

Why this paper matters

Allulose formulators know the usual story. Fructose goes in, allulose comes out, but the enzyme decides how much. That enzyme is the weak link. A new paper in Advanced Science (DOI: 10.1002/advs.202306478) takes a different approach to fixing it. Instead of testing thousands of mutants one by one, the researchers linked enzyme performance to cell survival. Then they let evolution do the screening.

Background

D-Allulose is a C3 epimer of D-fructose. You make it by isomerizing fructose with ketose 3-epimerases, or KEases. The trouble is that natural KEases are often slow and fragile. High temperatures speed the reaction but hurt the enzyme. So the industry needs better variants. Finding them is the bottleneck.

What the study did

The team built a growth-coupled in vivo screening platform. At the core is a D-allulose-dependent biosensor. Cells carrying an epimerase variant convert D-fructose to D-allulose. The D-allulose triggers the biosensor. The biosensor supports cell growth. No conversion, no growth. Weak mutants die. Strong mutants take over. That is natural selection with a purpose.

The paper calls this system Biosen. Using Biosen, the researchers applied evolutionary pressure to the KEase known as ADAE. They screened libraries of mutants and identified a standout: M42.

What M42 delivered

The numbers are clear.

Metric	M42 result	Why it matters
Catalytic activity	6.28-fold higher than the parent enzyme	Faster conversion, lower enzyme loading
Half-life at 60°C	2.5-fold longer	Holds up better under process heat
D-Allulose yield from D-fructose in 3 h	32.2%	Practical level for biosynthesis

Catalytic activity jumped 6.28 times. The half-life at 60°C stretched to 2.5 times that of the starting enzyme. In a 3-hour reaction, M42 converted 32.2% of D-fructose into D-allulose. Those improvements came from the same growth-coupled selection system. No random screening. No guesswork.

What it means for manufacturers

For ingredient buyers, the immediate value is not M42 itself. The lab results are encouraging, but commercial scale-up still lies ahead. The bigger value is Biosen. This platform gives researchers a high-throughput way to tailor biocatalysts for D-allulose synthesis. Faster and more stable enzymes mean less enzyme needed per kilo of allulose. That changes production costs. It also opens the door to adapting the sensor to other rare sugars or related enzymes. Supply chains could become less dependent on one enzyme source and more flexible.

Enzyme economics are hard to ignore. If you are evaluating allulose suppliers, ask about their enzyme strategy. Are they using old KEases? Are they evolving better ones? The difference will show up in price, capacity, and process reliability.

FAQ

Is M42 already used in commercial allulose production?

Not yet. This is a proof-of-concept study. M42 would need strain development, licensing, formulation, and regulatory approval. But the screening method is ready for wider use.

How does growth-coupled screening work?

It ties enzyme activity to cell growth. Only cells that produce D-allulose trigger the biosensor and grow. Weak variants die out. Strong variants multiply. That makes selection fast and automatic.

Can this help with sugars other than allulose?

The study focuses on KEases, which are relevant to allulose and other rare sugars. The same idea could be adapted if the right biosensor exists. The authors describe Biosen as a promising high-throughput tool for biocatalyst customization.

Closing thought

Enzymes are where allulose economics start. M42 shows what happens when you put evolution under pressure. The next improvement in allulose supply may come from a flask, not a plant.